Oncoustics AI
Beth Rogozinski has a diverse work experience in the healthcare and technology sectors. Beth currently serves as the Chief Executive Officer at Oncoustics, a company that utilizes AI to differentiate healthy and diseased tissues using ultrasound signals. Beth has been with the company since September 2020. In addition to their role at Oncoustics, Beth has held advisory positions at various organizations such as Modality.AI, UnitedHealth Group, A4i, Mentia, Inc., Neolth Inc., and FireflyVR. Beth is also an Independent Board Director at Modality.AI, A4i, and Koa Health. Furthermore, Beth has served as a Senior Advisor at the National Mental Health Innovation Center and as a UCSF Startup 101 Advisor/Mentor at the UCSF Entrepreneurship Center. Beth'sextensive experience in leadership and advisory roles highlights their expertise in healthcare technology and innovation.
Beth Rogozinski attended San Francisco State University, Lam Family College of Business, from 2003 to 2005, where they earned an MBA with a focus on Marketing and Management. Additionally, during the same period, they also pursued an MBA with a specialization in Marketing, Management, and Branding at San Francisco State University - CSU.
This person is not in any teams
This person is not in any offices
Oncoustics AI
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.